December 18, 2012

SLU Vaccine Researcher Named to NIH Panel

Belshe to Serve on NIAID Advisory Panel

ST. LOUIS -- Robert Belshe, M.D., director of Saint Louis University's Center for Vaccine Development, has been appointed to serve on the National Institutes of Health's (NIH) main advisory panel on allergies and infectious diseases.

Robert Belshe, M.D.

The group offers a broad perspective on the health, science and human impact of diseases.

Belshe, the Dianna and J. Joseph Adorjan Endowed Professor of Infectious Diseases and Immunology at Saint Louis University School of Medicine, will serve on the National Advisory Allergy and Infectious Diseases (NAAID) Council for four years.

He is one of 12 health and science experts in the nation who join six lay members in advising the National Institute of Allergy and Infectious Diseases on long-term planning and suggesting broad research priorities. The panel also evaluates NIAID programs and performs second-level reviews of some grants.

In addition to serving on the larger advisory panel, Belshe will be a member of the NAAID's microbiology and infectious diseases subcommittee.

Belshe is one of the foremost vaccine researchers in the country and has been on faculty at Saint Louis University since 1989. The principal investigator of the NIH-funded Vaccine and Treatment Evaluation Unit at SLU and an expert in designing and executing clinical trials, Belshe has conducted extensive research on the antibody responses to viral vaccines for diseases including influenza, genital herpes and smallpox. His findings have been published in the New England Journal of Medicine, JAMA, The Lancet and PNAS, among other peer-reviewed medical journals.

Established in 1836, Saint Louis University School of Medicine has the distinction of awarding the first medical degree west of the Mississippi River. The school educates physicians and biomedical scientists, conducts medical research, and provides health care on a local, national and international level. Research at the school seeks new cures and treatments in five key areas: cancer, infectious disease, liver disease, aging and brain disease and heart/lung disease.

Higher purpose. Greater good.
© 1818 - 2017  SAINT LOUIS UNIVERSITY   |   Disclaimer   |  Mobile Site
St. Louis   |   Madrid